# BioMarin Q3 financial results to see IPR&D expense impact of $283M — retained record

> Retained news record from news:seeking-alpha.

Canonical: https://highsignal.app/data/records/75f8cf257a81c0dc

[← sources](https://highsignal.app/data)


source: [news](https://highsignal.app/data/news) (news:seeking-alpha)  published 2026-10-06 22:28 ingested 2026-10-07 02:56

[original source ↗](https://seekingalpha.com/news/4650778-biomarin-q3-financial-results-see-ipr-and-d-expense-impact-283m?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news)

## retained text



```
Search fieldHome page Seeking Alpha - Power to InvestorsSearch for Symbols, analysts, keywordsAbout PremiumCreate free accountLog in

Earnings News

BioMarin Q3 financial results to see IPR&D expense impact of $283M

Oct 06, 2026, 6:28 PM ETBioMarin Pharmaceutical Inc. (BMRN) StockBy : Jonathan Block, SA News Editor

BioMarin Pharmaceutical (BMRN) said that it would incur an acquired in-process research and development (IPR&D) expense of $283M for Q3.

As a result, GAAP and non-GAAP diluted EPS for the quarter will be negatively impacted by $1.50.

The non-GAAP diluted EPS estimate for the quarter is $1.25.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Search fieldEntering text into the input field will update the search result below

Recommended For You
```



document fetched 2026-10-07 02:56 · canonical https://seekingalpha.com/news/4650778-biomarin-q3-financial-results-see-ipr-and-d-expense-impact-283m?feed_item_type=news